Cardio Diagnostics Holdings Inc (CDIO)vsBeiGene, Ltd. (ONC)
CDIO
Cardio Diagnostics Holdings Inc
$1.58
+1.28%
HEALTHCARE · Cap: $4.82M
ONC
BeiGene, Ltd.
$322.08
-1.57%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 34656857% more annual revenue ($5.74B vs $16,560). ONC leads profitability with a 8.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).
CDIO
Avoid33
out of 100
Grade: F
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.0%
Fair Value
$2.64
Current Price
$1.58
$1.06 discount
Margin of Safety
+81.1%
Fair Value
$1857.02
Current Price
$322.08
$1534.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 185.1% year-over-year
Conservative balance sheet, low leverage
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CDIO
The strongest argument for CDIO centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 185.1% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : CDIO
The primary concerns for CDIO are EPS Growth, Market Cap, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
CDIO carries more volatility with a beta of 2.18 — expect wider price swings.
CDIO is growing revenue faster at 185.1% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (54/100 vs 33/100) and 35.5% revenue growth. CDIO offers better value entry with a 50.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cardio Diagnostics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cardio Diagnostics Holdings Inc (CDIO) is an innovative biotechnology company dedicated to improving cardiovascular health through advanced diagnostic solutions. By harnessing cutting-edge technology, CDIO provides healthcare professionals with essential tools for accurate assessment and effective management of cardiovascular diseases, ultimately enhancing patient outcomes. With a strong focus on personalized medicine, the company is strategically poised for substantial growth, representing a compelling investment opportunity for institutional investors aiming to leverage advancements in the evolving healthcare landscape.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?